Retatrutide vs Tirzepatide: Triple Agonist vs Dual Agonist
Both retatrutide and tirzepatide are developed by Eli Lilly and Company, but they represent different generations of multi-receptor metabolic therapy. This educational comparison explains how they differ at the mechanism level and why direct efficacy comparisons remain premature.
Important Context
Retatrutide is an investigational compound not approved for any use. Tirzepatide is the active ingredient marketed as Mounjaro® and Zepbound®. This comparison is purely educational and mechanism-based. Retatrutide is not available for purchase.
Two Molecules, One Developer
Both tirzepatide and retatrutide were developed by Eli Lilly and Company, making them siblings in Lilly's metabolic drug pipeline. Tirzepatide is the older sibling — already approved and commercially available. Retatrutide is the newer molecule, still in clinical trials, and designed to build upon the multi-agonist approach that tirzepatide pioneered.
Understanding the relationship between these two molecules helps contextualize where the field of metabolic medicine is heading: from targeting one receptor to two, and now potentially to three.
Mechanism Comparison: Dual vs Triple
Tirzepatide
Dual Agonist (Approved)
- GLP-1: Appetite reduction, blood sugar control
- GIP: Improved fat metabolism, insulin sensitivity
- Glucagon: Not targeted
Retatrutide
Triple Agonist (Investigational)
- GLP-1: Appetite reduction, blood sugar control
- GIP: Improved fat metabolism, insulin sensitivity
- Glucagon: Energy expenditure, fat oxidation
The Glucagon Receptor: What It Adds
The key differentiator between retatrutide and tirzepatide is the glucagon receptor component. While both molecules share GLP-1 and GIP receptor agonism, retatrutide adds a third target that addresses a fundamentally different aspect of energy balance.
The Energy Balance Equation
Energy In (Both Molecules)
GLP-1 and GIP agonism reduce appetite, slow gastric emptying, and improve metabolic processing of food. This reduces "energy in" — how many calories the body takes in and absorbs.
Energy Out (Retatrutide Only)
Glucagon receptor agonism increases energy expenditure, promotes fat oxidation, and has thermogenic effects. This increases "energy out" — how many calories the body burns.
The theoretical advantage of addressing both sides of the energy equation is intuitive: reducing intake while simultaneously increasing expenditure creates a wider energy deficit. However, the practical significance of this in long-term clinical outcomes is still being evaluated in the ongoing TRIUMPH Phase 3 trial program.
A note on glucagon's blood sugar effects: Glucagon naturally raises blood sugar, which could be counterproductive for patients with diabetes or insulin resistance. The design hypothesis of retatrutide is that the GLP-1 and GIP components counterbalance this effect, maintaining blood sugar control while capturing the energy expenditure benefits. Phase 2 data published in the NEJM showed that this balance was maintained in study participants.
Side-by-Side Comparison
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| Molecule Type | Dual GLP-1/GIP agonist | Triple GLP-1/GIP/Glucagon agonist |
| Developer | Eli Lilly | Eli Lilly |
| Internal Code | LY3298176 | LY3437943 |
| Regulatory Status | FDA Approved (2022) | Phase 3 (Investigational) |
| Brand Names | Mounjaro®, Zepbound® | Not yet branded |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Trial Program | Phase 3 trials (diabetes and obesity) | TRIUMPH (obesity, multiple indications) |
| Primary Mechanism | Appetite reduction + fat metabolism | Appetite reduction + fat metabolism + energy expenditure |
| Available for Purchase? | Yes (prescription required) | No — Not approved anywhere |
Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. This comparison is for educational purposes only.
Development Timelines
Tirzepatide has a significant head start in development, having already completed clinical trials and received regulatory approval. Retatrutide is following a similar but separate path through the clinical trial process.
Tirzepatide Approved
Retatrutide Investigational
Why Direct Efficacy Comparisons Are Premature
It may be tempting to compare weight loss percentages from tirzepatide's and retatrutide's respective clinical trials. However, such comparisons are scientifically problematic for several reasons:
- 1 Different trial populations: Patient demographics, baseline weight, comorbidities, and other characteristics differ between trials, making cross-trial comparisons unreliable.
- 2 Different trial phases: Retatrutide's most prominent published data is from a Phase 2 trial (smaller, shorter), while tirzepatide has extensive Phase 3 data (larger, longer).
- 3 No head-to-head trial: A valid comparison requires a randomized controlled trial where both drugs are tested in the same patient population under the same conditions. No such trial exists.
- 4 Different dosing schedules: The optimal dose for retatrutide is still being determined in Phase 3 trials, while tirzepatide dosing is well-established.
Bottom line: While retatrutide's Phase 2 data is promising, claiming it is "better" or "more effective" than tirzepatide based on cross-trial comparisons is not scientifically supported. The TRIUMPH Phase 3 program will provide the data needed to understand retatrutide's true clinical profile.
The Future of Multi-Agonist Therapies
The progression from single to dual to triple agonism reflects a broader trend in metabolic medicine: targeting multiple biological pathways simultaneously to address the complexity of obesity and metabolic disease.
If retatrutide's Phase 3 results confirm the Phase 2 findings and it receives regulatory approval, it would represent the next generation of incretin-based therapy. However, several factors will determine its real-world impact:
- • Tolerability: Whether the addition of glucagon agonism results in more or different side effects than dual-agonist therapy.
- • Accessibility: Pricing, insurance coverage, and global availability — particularly for markets like Nigeria.
- • Long-term data: Safety and efficacy over years, not just months.
- • Regulatory timelines: When and if it receives approval in the US, EU, and eventually in African markets.
Beyond retatrutide, researchers are already exploring quadruple agonists and other novel combinations. The metabolic medicine landscape is evolving rapidly, and multi-agonist approaches represent a significant frontier in obesity treatment research.
Track Retatrutide Progress
Join our research watchlist for updates on the TRIUMPH trial program and regulatory milestones. Educational interest only.
Join the WaitlistThis is not an order form. Retatrutide is not available for purchase.
References
- 1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526. doi:10.1056/NEJMoa2301972. PMID: 37351564.
- 2. Eli Lilly and Company. TRIUMPH-4 Phase 3 Trial Positive Topline Results. Press Release, December 11, 2025.
- 3. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385:503-515. PMID: 34170647.
- 4. ClinicalTrials.gov. TRIUMPH Program — Retatrutide Phase 3 Clinical Trials. National Library of Medicine.
Medical Review: This article was prepared by the Retatrutide.ng editorial team for educational purposes. It is based on publicly available research and does not constitute medical advice. Always consult a qualified healthcare professional for medical decisions.